home / stock / oxnxf / oxnxf news
2024-05-01 09:50:50 ET More on Valerio Therapeutics Société anonyme Financial information for Valerio Therapeutics Société anonyme Read the full article on Seeking Alpha For further details see: Valerio Therapeutics Société anonyme r...
Onxeo SA press release ( OTC:OXNXF ): 1H GAAP EPS of -€0.11. The Group has not recorded any consolidated revenues for the period ended June 30, 2022. At June 30, 2022, the Group's cash position was €26.9 million, compared to €17.9 million euros at Dece...
French biotech Onxeo ( OTC:OXNXF ) on Thursday said the U.S. FDA had cleared its initial investigational new drug (IND) application for its oncology drug AsiDNA. OXNXF can now start a phase 1b/2 trial to evaluate AsiDNA in combination with olaparib (a type of targeted can...
Onxeo S.A. (OTC:OXNXF) has appointed Dr. Shefali Agarwal as President and CEO to succeed Julien Miara, a Principal at Invus SAS, who was named interim CEO in January 2022. Dr. Agarwal is a physician by training, and, until recently, was the Chief Medical and Development Officer at Epizym...
Onxeo SA (OTC:OXNXF): Q2 GAAP EPS of -$0.06. Revenue of $589M Press Release For further details see: Onxeo SA reports Q2 results
European Patent Office has issued notice of intent to grant a patent to Onxeo ([[OXNXF]]) related to AsiDNA, its first-in-class inhibitor of tumor DNA repair in combination with PARP inhibitors (PARPi). This patent will provide a term of protection until 2036.This pat...
Onxeo ( OTC:OXNXF ) announces the confirmation of the preclinical profile of its new drug candidate from platON oligonucleotides platform, OX401, a next-gen PARP inhibitor. More news on: Onxeo SA, Healthcare stocks news, Read more ...
Onxeo SA ( OTC:OXNXF ): 1H GAAP EPS of -€0.15. More news on: Onxeo SA, Earnings news and commentary, , Read more ...
Onxeo SA ( OTC:OXNXF ): FY GAAP EPS of -€0.18. More news on: Onxeo SA, Earnings news and commentary, , Read more ...